*Viro-immunological, clinical and psychosocial correlates of disease severity and long-term outcomes of infection in SARSCoV-2 - a prospective cohort study*: *the VIS cohort study
Recruiting
- Conditions
- CoronaCOVID191004743810024970
- Registration Number
- NL-OMON56179
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
- informed consent documented by signature
- age between 16 - 85 years
- sufficient understanding of Dutch or English
Exclusion Criteria
- Unlikely to comply with the study procedures, as deemed by the recruiting
research doctor/nurse
- mental disorder that in the view of the investigator would interfere with
adherence to the study procedures, or the decision to participate in the study.
- Investigators or otherwise dependent persons
- living in long term care facility
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1: To identify socio-demographic, clinical, virological and/or host factors<br /><br>predictive of disease progression<br /><br><br /><br>2: To investigate the induction of lasting protective SARS-CoV-2-specific<br /><br>antibody (titers and breadth) and SARS-CoV-2-specific T cell responses (numbers<br /><br>and quality) in relation to disease severity, clinical recovery and patient<br /><br>characteristics or re-infection over time;<br /><br><br /><br>3: Asses the mid-term (4 weeks - 3 months post diagnosis) and long-term (until<br /><br>2 year post diagnosis) sequelae of individuals who have experienced a<br /><br>SARS-CoV-2 infection, particularly with respect to respiratory function,<br /><br>socio-psychological outcomes and quality of life.</p><br>
- Secondary Outcome Measures
Name Time Method <p>(4) To gain insight in the immune response after vaccination<br /><br><br /><br>5: To investigate influenza vaccine responses in the context of waning immunity<br /><br>after prolonged absence of influenza circulation;<br /><br><br /><br>6: To establish a well characterised data-and biobank for future in-depth<br /><br>pathophysiological, immunological, host-genetic and further clinical and<br /><br>epidemiologic studies.<br /><br><br /><br>Substudy objectives<br /><br>7: To investigate risk factors (demographic, clinical, virological,<br /><br>immunological) for SARS-CoV-2 reinfections.<br /><br><br /><br>8: To understand which factors determine the longevity and breadth of<br /><br>protective SARS-CoV-2-specific humoral and cellular immunity.<br /><br><br /><br>9: To determine the health impact of SARS-CoV-2 reinfections or their sequelae. </p><br>